Hubei Biocause Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Hubei Biocause Pharmaceutical has a total shareholder equity of CN¥36.0B and total debt of CN¥17.5B, which brings its debt-to-equity ratio to 48.6%. Its total assets and total liabilities are CN¥285.2B and CN¥249.1B respectively.
Key information
48.6%
Debt to equity ratio
CN¥17.49b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥10.77b |
| Equity | CN¥36.00b |
| Total liabilities | CN¥249.15b |
| Total assets | CN¥285.15b |
Recent financial health updates
No updates
Recent updates
Hubei Biocause Pharmaceutical Co., Ltd.'s (SZSE:000627) Shares Leap 43% Yet They're Still Not Telling The Full Story
Oct 23
Further Upside For Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Could Introduce Price Risks After 32% Bounce
Sep 05Improved Revenues Required Before Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627) Shares Find Their Feet
Jun 10Fewer Investors Than Expected Jumping On Hubei Biocause Pharmaceutical Co., Ltd. (SZSE:000627)
Mar 05Financial Position Analysis
Short Term Liabilities: 000627's short term assets (CN¥33.9B) exceed its short term liabilities (CN¥17.4B).
Long Term Liabilities: 000627's short term assets (CN¥33.9B) do not cover its long term liabilities (CN¥231.7B).
Debt to Equity History and Analysis
Debt Level: 000627's net debt to equity ratio (18.6%) is considered satisfactory.
Reducing Debt: 000627's debt to equity ratio has increased from 10% to 48.6% over the past 5 years.
Debt Coverage: 000627's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 000627's interest payments on its debt are well covered by EBIT.